Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46.

Johnson DH, Paul DM, Hande KR, DeVore RF
Semin Oncol. 1995 22 (4 Suppl 9): 30-3

PMID: 7644925

Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with previously untreated stage IIIB and IV non-small cell lung cancer. Among 51 patients treated, the overall response rate was 27.5% (14 partial responses). Seventeen patients had stable disease, while 16 patients experienced disease progression after two cycles of treatment. Apart from myelosuppression, toxicity has been modest, with fewer than 5% of patients experiencing grade 3 or greater nonhematologic toxicity. Objective response and survival rates were modestly improved among patients given the higher of two paclitaxel doses (175 mg/m2 v 135 mg/m2). These data suggest that paclitaxel plus carboplatin warrants further study in metastatic non-small cell lung cancer.

MeSH Terms (19)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Bone Marrow Carboplatin Carcinoma, Non-Small-Cell Lung Cohort Studies Disease Progression Female Humans Lung Neoplasms Male Middle Aged Neoplasm Staging Paclitaxel Remission Induction Survival Rate Tennessee Thrombocytopenia

Connections (1)

This publication is referenced by other Labnodes entities: